MESO Earnings Prediction
The chart below shows how MESO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MESO sees a +1.58% change in stock price 10 days leading up to the earnings, and a -0.47% change 10 days following the report. On the earnings day itself, the stock moves by -0.23%. This data can give you a slight idea of what to expect for the next quarter's release.
MESO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
MESO Earnings Analysis
Mesoblast Limited American Depositary Shares Corporation (MESO.O) Earnings Conference Call
Positive
Cash Balance and Facility Approval: At June 30, our cash balance was US$63.3 million with an additional US$10 million from an existing facility on FDA approval of RYONCIL.
Q4 Spending Reduction: We recorded a 37% reduction of $6.1 million for Q4 in FY '24 compared to the prior comparative quarter, with Q4 spend down to $10.2 million compared to $16.3 million in the prior comparative quarter.
Loss After Tax Improvement: Our loss after tax for FY '24 is $78.3 million, a $12.4 million improvement on FY 2023.
FDA BLA Resubmission Accepted: The FDA accepted the BLA resubmission for RYONCIL within two weeks, considering it to be a complete response, with a PDUFA goal date of January 7, 2025.
Manufacturing Cost Reduction: We achieved a significant 43% reduction in manufacturing expenditure, amounting to $12 million due to decreased inventory build and one-off FY '23 expenditure.
Negative
Improvement in Loss After Tax: Loss after tax for FY '24 is $88 million, a $12.4 million improvement on FY 2023, indicating ongoing financial challenges.
Manufacturing Expenditure Decline: Manufacturing expenditure reduced by $12 million, a significant 43% decrease, reflecting reduced operational activities rather than growth.
Cash Usage Reduction: Net operating cash usage for FY 2024 was $48.5 million, down from $63.3 million in FY 2023, highlighting continued cash burn despite reductions.
Contingent Consideration Revaluation: The company recorded a significant swing in revaluation of contingent consideration, impacting financial stability and future projections.
Deferred Cash Payments: Cash payment of STI earned during FY '23 and FY '24 is deferred until FDA BLA approval, indicating reliance on future approvals for financial stability.
MESO FAQs
How does MESO typically perform around its earnings report dates?
Is Mesoblast Limited (MESO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MESO Earning Call Sentiment
Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript
1.0x
00:00
00:00
MESO.O
-2.36%Positive
The earnings call summary shows mixed signals: reduced cash usage and improved loss after tax are positive, but high cash burn and regulatory risks remain. The Q&A reveals unclear timelines for REVASCOR, adding uncertainty. Lack of new partnerships or guidance adjustments further tempers optimism. Thus, the stock price reaction is likely neutral, with no strong catalysts for a significant move.
